Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

Healthcare Biotechnology
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Grail even less accurate than previously thought
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(445)
•••
Comment by Liked2Thinkon Oct 14, 2022 11:40am
109 Views
Post# 35024845

RE:Grail even less accurate than previously thought

RE:Grail even less accurate than previously thought
LithLover wrote: Grail test found to have even more false positives than before. Imagine taking the test being told you have cancer and than finding out the test was only 38% accurate.  

29.8% of the participants with false alarms underwent invasive procedures

Sept 12, 2022

https://www.medtechdive.com/news/amid-merger-turmoil-illuminas-grail-unit-reports-downturn-in-accuracy-of/631583/

  • Updated data on Grail’s multi-cancer early detection blood test Galleri suggest the diagnostic is less accurate than previously thought. 
  • Last year, Grail reported that 44.6% of patients with positive test results actually had cancer. In the latest analysis, the figure, known as the positive predictive value, has fallen to 38.0%.
  • News of the falling predictive power seen in the study, which used an old version of Galleri, comes amid growing doubts about the fate of the Illumina-Grail merger, which the European Commission has blocked.




Has there ever been any 3rd party verification that the Aristotle test is any better or is that just another thing investors should just believe from a ceo that hasn't been able to keep his word multiple times in the past?

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities